Point72 Asset Management L.P. Sells 179,451 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Point72 Asset Management L.P. decreased its stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 28.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 451,318 shares of the company's stock after selling 179,451 shares during the period. Point72 Asset Management L.P. owned about 0.84% of EyePoint Pharmaceuticals worth $3,606,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. California State Teachers Retirement System raised its position in EyePoint Pharmaceuticals by 884.2% in the first quarter. California State Teachers Retirement System now owns 43,275 shares of the company's stock valued at $894,000 after purchasing an additional 38,878 shares during the last quarter. SG Americas Securities LLC bought a new position in EyePoint Pharmaceuticals in the 2nd quarter valued at approximately $664,000. Bank of New York Mellon Corp boosted its position in EyePoint Pharmaceuticals by 32.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 204,892 shares of the company's stock worth $1,783,000 after buying an additional 50,388 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in EyePoint Pharmaceuticals by 271.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company's stock worth $95,000 after buying an additional 7,953 shares during the period. Finally, Panagora Asset Management Inc. grew its holdings in EyePoint Pharmaceuticals by 205.5% during the 2nd quarter. Panagora Asset Management Inc. now owns 120,721 shares of the company's stock worth $1,050,000 after acquiring an additional 81,201 shares during the last quarter. Institutional investors own 99.41% of the company's stock.

EyePoint Pharmaceuticals Price Performance

Shares of EyePoint Pharmaceuticals stock traded up $0.24 on Monday, reaching $8.95. 407,806 shares of the company's stock were exchanged, compared to its average volume of 935,171. EyePoint Pharmaceuticals, Inc. has a 52 week low of $7.40 and a 52 week high of $30.99. The firm's 50-day moving average is $9.81 and its two-hundred day moving average is $9.29.

Analysts Set New Price Targets

EYPT has been the topic of a number of recent research reports. Chardan Capital lifted their price target on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a "buy" rating in a report on Friday, November 8th. JPMorgan Chase & Co. decreased their price target on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an "overweight" rating for the company in a research note on Tuesday, August 13th. Scotiabank started coverage on EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $18.00 price objective on the stock. Robert W. Baird reduced their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a report on Monday, November 11th. Finally, HC Wainwright restated a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to MarketBeat.com, EyePoint Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $28.00.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.